Last reviewed · How we verify
topiramate, phenytoin
Topiramate is an anticonvulsant that works by blocking voltage-dependent sodium channels, stabilizing neuronal membranes, and reducing the release of excitatory neurotransmitters.
Topiramate is an anticonvulsant that works by blocking voltage-dependent sodium channels, stabilizing neuronal membranes, and reducing the release of excitatory neurotransmitters. Used for Seizure prevention in patients with epilepsy, Migraine prevention.
At a glance
| Generic name | topiramate, phenytoin |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Anticonvulsant |
| Target | Voltage-dependent sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Topiramate's mechanism of action is complex and multifaceted, involving the blockade of voltage-dependent sodium channels, which reduces the frequency and severity of seizures. Additionally, topiramate stabilizes neuronal membranes and reduces the release of excitatory neurotransmitters, such as glutamate, which can contribute to seizure activity. This results in a decrease in the excitability of neurons and a reduction in the likelihood of seizure occurrence.
Approved indications
- Seizure prevention in patients with epilepsy
- Migraine prevention
Common side effects
- Dizziness
- Headache
- Fatigue
- Nausea
- Dyspepsia
Key clinical trials
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
- Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy (NA)
- Multicentre Study on Rapid Versus Slow Withdrawal of Antiepileptic Monotherapy (NA)
- Characterization of Epilepsy Patients BEEP 2b (PHASE1)
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma (PHASE1, PHASE2)
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (PHASE3)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: